Lifesciences@Work : We help scientists build their business

Venture Challenge Alumni Cristal Therapeutics announces strategic partnership with iTeos Therapeutics.

Cristal Therapeutics and iTeos Therapeutics announce strategic partnership for the development of immuno-oncology therapeutic candidates using Cristal’s CriPec® nanotech platform.

The initial goal is to determine treatment efficacy of iTeos’ immuno-oncology drug candidates Option for iTeos to license Cristal’s proprietary nanotechnology platform for development of up to three immuno-oncology therapeutic candidates   Maastricht, The Netherlands and Gosselies, Belgium.

Read the full article.